BioSpace News Archive

Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today that Capricor’s CEO, Linda Marbán, Ph.D, will participate on the panel “ Cell therapy for ARDS - When Remdesivir is not enough " hosted by Maxim Group and M-Vest on Wednesday, May 27 beginning at 10:00 a.m. Eastern time (7:00 a

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it received the CE mark for the WRAPSODY™ Endovascular Stent Graft System from the British Standards Institution (BSI).

Todos gains distribution rights to LifeCan Ventilator in Brazil, Mexico & Latin America Ventilator access will help prospective government and NGO procurers of COVID-related medical products reduce need for additional suppliers to address critical health needs L1 distribution network will provide untapped market access for Todos’ tests REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 26, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , an in vi

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS (or ADS equivalent). The closing of the offering is expected to

Expression Therapeutics has announced that it has received clearance by the United States Food and Drug Administration (FDA) to proceed following review of its Investigational New Drug Application (IND) for clinical testing of its novel lentiviral vector-based gene therapy — ET3 — for hemophilia A. Hemophilia A is the most common severe congen

BioArctic AB (publ) ( Nasdaq Stockholm : BIOA B ) announces that seven members of the company’s Board and management today have exercised options to purchase shares in the company in accordance with the existing option agreements with the principal owners of BioArctic AB. Seven members of BioArctic’s Board of Directors and management,

XENDEE Corporation has signed a contract with the US Department of Defense (DoD) to develop the Standardized Platform to Guide Rapid and Repeatable Modelling and Design of Secure and Resilient DoD Microgrids globally. XENDEE has been tasked to deliver design solutions that enhance energy reliability, while providing new services such as the ability to safely ride-out prolonged utility power outages and sustain mission critica

Bexson Biomedical, Inc. today announced the expansion of its Board of Directors with the additions of Belinda Tan, MD, PhD and Itai Danovitch, MD, MBA.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.61 per share of the company’s common stock for the second quarter of 2020.

Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform announced its participation in the following upcoming investor conferences